Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.76 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 5/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 2/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
| ▸ | FES | P07332 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655988 | 0.88 | AURKA (0.65) | AURKALRRK2CDK2MAPK8CDK5 | |
| SCHEMBL655986 | 0.82 | AURKA (0.55) | AURKALRRK2CDK2MAPK8CDK5 | |
| SCHEMBL656320 | 0.82 | AURKA (0.58) | AURKACDK2MAPK8CDK5JAK2 | |
| SCHEMBL655868 | 0.82 | AURKA (0.58) | AURKACDK2MAPK8CDK5JAK2 | |
| SCHEMBL12439807 | 0.81 | IGF1R (0.68) | AURKALRRK2CDK2MAPK8CDK5 | |
| SCHEMBL656813 | 0.81 | AURKA (0.84) | AURKACDK2MAPK8CDK5JAK2 | |
| SCHEMBL30033308 | 0.81 | AURKA (0.60) | AURKACDK2MAPK8CDK5JAK2 | |
| SCHEMBL655352 | 0.81 | AURKA (0.77) | AURKALRRK2CDK2MAPK8CDK5 | |
| SCHEMBL23409136 | 0.80 | AURKA (0.67) | AURKAJAK2LYNSYKJAK3 | |
| SCHEMBL653923 | 0.80 | AURKA (0.58) | AURKACDK2MAPK8CDK5JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150349-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | AURKA 997/4885LRRK2 1165/4885CDK2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.